Nanovehicles for co-delivery of anticancer agents

Mahdi Zeinali; Soheil Abbaspour-Ravasjani; Marjan Ghorbani; Afshin Babazadeh; Tannaz Soltanfam; Ana Cláudia Santos; Hamed Hamishehkar; Michael R Hamblin

doi:10.1016/j.drudis.2020.06.027

Nanovehicles for co-delivery of anticancer agents

Drug Discov Today. 2020 Aug;25(8):1416-1430. doi: 10.1016/j.drudis.2020.06.027. Epub 2020 Jul 2.

Authors

Mahdi Zeinali¹, Soheil Abbaspour-Ravasjani², Marjan Ghorbani³, Afshin Babazadeh⁴, Tannaz Soltanfam⁵, Ana Cláudia Santos⁶, Hamed Hamishehkar⁷, Michael R Hamblin⁸

Affiliations

¹ Student Research Committee and Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran; Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
² Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; Student's Scientific Research Center and Department of Medical Nanotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.
³ Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
⁴ Department of Biomedical Sciences, Faculty of Medicine, Health, and Human Sciences, Macquarie University, Sydney, NSW 2109, Australia.
⁵ Student Research Committee and Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.
⁶ Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Coimbra, Coimbra, Portugal; REQUIMTE/LAQV, Group of Pharmaceutical Technology, Faculty of Pharmacy, University of Coimbra, Coimbra, Portugal.
⁷ Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. Electronic address: Hamishehkarh@tbzmed.ac.ir.
⁸ Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, MA 02114, USA; Department of Dermatology, Harvard Medical School, Boston, MA 02115, USA; Laser Research Centre, Faculty of Health Science, University of Johannesburg, Doornfontein 2028, South Africa. Electronic address: hamblin@helix.mgh.harvard.edu.

PMID: 32622880
DOI: 10.1016/j.drudis.2020.06.027

Abstract

Effective cancer treatment remains a significant challenge in human healthcare. Although many different types of cancer therapy have been tested, scientists have now concluded that combinations of drugs, or drugs plus gene therapy, can target multiple pathways to fight cancer. Nanovehicles can increase drug uptake inside tumor cells, improve biodistribution and accumulation at tumor sites. The ability to deliver two or more anticancer drugs, genes, among others, at the same time and place will increase therapeutic effects while decreasing side effects and reducing the risk of multidrug resistance. This review discusses the advantages of nano-based co-delivery methods in cancer therapy, summarizes the common types of nanovehicles and their preparation methods, and covers some recent co-delivery studies in detail.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Review

MeSH terms

Animals
Antineoplastic Agents / administration & dosage*
Drug Delivery Systems*
Humans
Nanoparticles / administration & dosage*
Neoplasms / drug therapy*

Substances

Antineoplastic Agents

Abstract

Publication types

MeSH terms

Substances

Grants and funding